Second of two planned phase III pivotal trials of autologous cell therapy utilising tumour infiltrating lymphocytes [Contego] as second-line therapy in patients with stage IV metastatic melanoma.
Phase of Trial: Phase III
Latest Information Update: 13 Oct 2011
At a glance
- Drugs LN 144 (Primary)
- Indications Malignant melanoma
- Focus Adverse reactions; Registrational; Therapeutic Use
- 13 Oct 2011 New trial record